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Liang Wang1,2, Yang Liu1,2, Xuyong Lin1,2, Di Zhang1,2, Qingchang Li1,2, Xueshan Qiu1,2 and En-Hua Wang1,2*Abstract: Low-grade cribriform cystadenocarcinoma (LGCCC) is a recently described rare tumor of salivary gland
which exhibits clinically indolent behavior. This tumor predominantly consists of intraductal components and
frequently exhibits papillary-cystic or cribriform proliferation pattern. Considering the histological features of LGCCC,
it should be distinguished with papillocystic variant of acinic cell carcinoma, conventional salivary duct carcinoma,
cystadenocarcinoma, polymorphous low-grade adenocarcinoma, carcinoma ex pleomorphic adenoma and
mammary analogue secretory carcinoma. Herein, we presented two cases of LGCCC. One arose in the left parotid
region in a 48-year-old male, and the other one arose in the right parotid gland in a 59-year-old female. For both
cases, immunohistochemically, the luminal tumor cells showed diffuse expression of CK and S100; p63 and smooth
muscle actin displayed a continuous rim of myoepithelial cells around all tumor islets; no myoepithelial cells were
admixed with the luminal cells. Both patients were alive with no tumor recurrence or metastasis at follow-up.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2593621568999135
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Low-grade cribriform cystadenocarcinoma (LGCCC) is a
rare neoplasm of salivary gland. Originally, it was
described as a variant of salivary duct carcinoma (SDC)
by Delgado et al. in 1996 [1]. LGCCC usually occurs in
elder people with a female predominance of 2:1. Parotid
gland is the most common site of involvement [1-6].
Presentation in the palate [7], submandibular gland [2],
intraparotid lymph node [2,6] and accessory parotid
gland [8] may occur but rare. LGCCC is characterized
by the papillary-cystic or cribriform proliferation pattern
and resembles the low-grade ductal carcinoma in situ or
atypical ductal hyperplasia of the breast in histology and
biological features. LGCCC was originally denominated
as low-grade salivary duct carcinoma (LGSDC) in order
to distinguish with the conventional SDC. In contrast
with the LGCCC, conventional SDC exhibits highly
aggressive malignancy and high-grade histology similar* Correspondence: wangeh775@gmail.com
1Department of Pathology, the First Affiliated Hospital and College of Basic
Medical Sciences, China Medical University, Shenyang 110001, China
2Institute of Pathology and Pathophysiology, China Medical University,
Shenyang 110001, China
© 2013 Wang et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orto an invasive ductal carcinoma of the breast. However,
no definite association was found between LGCCC and
conventional SDC; therefore, the third WHO classification
regards this neoplasm as a variant of cystadenocarcinoma
due to its cystic morphology [9].
Histologically, LGCCC was composed of single or
multiple cystically enlarged ducts accompanied by adja-
cent intraductal proliferation. Various structures, such as
cystic structures, loose cribriform and micropapillae pat-
tern or solid area, could be observed in LGCCC. The
typical cyst structures are lined by small or multilayered
mild ductal cells with finely dispersed chromatin and
small nucleoli. These tumor cells are diffusely strong
positive for S100. Myoepithelial markers highlight the
tumor cells rimming the cystic spaces, confirming the
intraductal nature of LGCCC. Based on the histological
features, LGCCC should be distinguished with other
common parotid tumors including papillocystic variant
of acinic cell carcinoma (PCV-ACC), conventional SDC,
cystadenocarcinoma, polymorphous low-grade adenocar-
cinoma (PLGA), carcinoma ex pleomorphic adenoma
and mammary analogue secretory carcinoma (MASC).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.




A 48-year-old male was admitted to the First Affiliated
Hospital of China Medical University in August of 2011
for further examination because of the mass in the left
parotid region. The mass was soft, non-tender and did not
adhere to the skin. Ultrasound examination revealed a
nonhomogenous hypoechogenic mass with anechogenic
areas measuring 21×12 mm. Examination by fine needle
aspiration cytology was not performed. The patient under-
went parotidectomy without radiotherapy. The patient
was alive with no tumor recurrence or metastasis at 16
months of follow-up.
Gross features
The surgical specimen measured 3.5 cm in the greatest
diameter. On cut surface, it showed a nonencapsulated
tumor measured 2×1 cm. The tumor was whitish in color.
Microscopic features
The tumor was demarcated from the surrounding slightly
lipomatous parotid glands with a relative boundary
(Figure 1A and B). The lesion was dominated by a large
cystic space with multiple small well demarcated tumor
islets in the fibrous stroma close to the central cyst. The
architecture of these islets varied from solid (Figure 1C) to
cribriform and micropapillary (Figure 1D). Within the
lumen, pink secretions could be observed, but no comedo
necrosis was identified. The tumor cells were uniform
without significant cytologic and nuclear atypia. They
displayed round to oval nuclei with fine chromatin and
prominent nucleoli and pale to amphophilic cytoplasm.
Apocrine differentiation of tumor cells was not obvious.
No atypical mitosis was observed.
Immunohistochemistry
Immunohistochemically, the luminal tumor cells
showed diffuse expression of CK and S100 (Figure 1I).
Immunostaining for p63 (Figure 1J) and SMA
displayed a continuous rim of myoepithelial cells
around all tumor islets. No myoepithelial cells were
admixed with the luminal cells. Tumor cells were nega-
tive for CEA, AR, ER, PR, EGFR, and Her-2/neu
oncoprotein. Ki67 index was less than 5%.
Case 2
A 59-year-old female was admitted to the First Affiliated
Hospital of China Medical University in May of 2012 for
further examination because of the mass in the right
parotid region. The physical examination showed a solid
mass in the right parotid with slight tender and the mass
did not adhere to the skin. Ultrasound examination
revealed a homogenous hypoechogenic mass measuring35×21×22 mm. Examination by fine needle aspiration
cytology was not performed. The patient underwent
parotidectomy without radiotherapy. The patient was alive
with no tumor recurrence or metastasis at 7 months of
follow-up.
Gross features
The surgical specimen measured 4 cm in the greatest
diameter. On cut surface, it showed a well-circumscribed
tumor measured 3×2 cm. The tumor was whitish in color.
Microscopic features
The tumor was demarcated from the surrounding par-
otid glands with a clear boundary (Figure 1E and F). The
lesion was mainly composed of solid to cribriform and
micropapillary structures, while the dilated cystic
structures were rarely seen. No comedo necrosis was
identified. The tumor cells were uniform without signifi-
cant cytologic and nuclear atypia. They displayed round
to oval nuclei with fine chromatin and pale to amphophilic
cytoplasm (Figure 1G). Apocrine differentiation of tumor
cells was observed locally (Figure 1H). No atypical mitosis
was observed.
Immunohistochemistry
Immunohistochemically, the luminal tumor cells showed
diffuse expression of CK, CK7 and S100 (Figure 1I).
Immunostaining for p63 (Figure 1J) and smooth muscle
actin (SMA) displayed a continuous rim of myoepithelial
cells around all tumor islets. No myoepithelial cells were
admixed with the luminal cells. Tumor cells were negative
for CK20, AR, ER, PR, EGFR, and Her-2/neu oncoprotein.
Ki67 index was less than 5%.
Discussion
Like other rare tumors in parotid glands, LGCCC is a low-
grade malignant tumor with indolent clinical behavior
[10-12]. In the third WHO classification, it is listed under
a separate heading although regarding as a variant of
cystadenocarcinoma [9]. To date, there are nine papers to-
tally reported 35 cases of LGCCC. The reported cases and
the two cases in this paper were summarized in Table 1.
In these patients, the majority of LGCCC occurred in
older patients (median 62 years) without obvious gender
preponderance (Male: Female=15:21; one case with gender
unavailable) though the third WHO classification
described that the tumor had a female predominance.
Among the cases listed in Table 1, thirty-five tumors arose
from parotid glands both in the superficial and deep lobes,
including three cases occurred in the intraparotid lymph
node and one occurred in accessory parotid gland. The
remaining two tumors arose in the palate and subman-
dibular gland. Therefore, all the LGCCCs reported by now
occurred in large salivary glands except one controversial
Figure 1 Histological features and immunohistochemical staining of both cases. A-B: Case 1, the tumor was demarcated from the
surrounding slightly lipomatous parotid glands with a relative boundary. C-D: Case 1, within the tumor, solid and micropapillary pattern were
observed. E-F: Case 2, the tumor was demarcated from the surrounding parotid glands with a clear boundary. G: Case 2, the tumor cells were
uniform without significant cytologic and nuclear atypia. They displayed round to oval nuclei with fine chromatin and pale to amphophilic
cytoplasm. H: Case 2, Apocrine differentiation of tumor cells was observed focally. I: The luminal tumor cells showed diffusive expression of S100
(Case 1 and 2). J: Immunostaining for p63 displayed a continuous rim of myoepithelial cells around all tumor islets (Case 1 and 2).
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Table 1 Reported cases of the low-grade cribriform cystadenocarcinoma in the English-Language Literature and their
prognosis




58 M Parotid (superficial lobe) 1 cm Superficial parotidectomy not mentioned
2 62 F Parotid 0.7 cm Parotidectomy not mentioned
3 32 F Right parotid (superficial lobe) 1.1 cm Parotidectomy, radiotherapy NED, 144 mos
4 63 M Right parotid (superficial lobe) 1.3 cm Parotidectomy NED, 132 mos
5 74 M Left parotid 1.8 cm Parotidectomy NED, 72 mos
6 56 F Right parotid 1 cm Parotidectomy NED, 24 mos




4 cm Parotidectomy NED, 24 mos
9 69 M Left parotid 0.9 cm Parotidectomy -










F 8 cases M 7
cases U 1 case
Parotid 15 cases (including one






13 82 NED, 44 mos
14 78 NED, 17 mos
15 72 NED, 108 mos
16 93 NED, 24 mos
17 NED, 30 mos
18 NED, 62 mos
19 64 Submandibular gland 1 case NED, 33 mos
20 66 Not mentioned
21 57 NED, 30 mos
22 63 Not mentioned
23 64 NED, 6 mos
24 62 NED, 132 mos
25 72 NED, 40 mos
26 76 NED, 24 mos




50 F Right parotid 2 cm Superficial parotidectomy NED, 5 mos




30 67 F Right parotid 2.5 cm
Right total parotidectomy and
chemotherapy and radiation therapy Not mentioned




50 F Right parotideomasseteric area 1.5 cm Enucleation of the tumor NED, 24 mos
33
Nakatsuka et al.
2011 27 M Accessory parotid gland 1.5 cm Local excision of the tumor NED, 3 mos







3.5 cm Not mentioned Not mentioned
36 Current case 48 M Left parotid 2cm Parotidectomy NED, 16 mos
37 Current case 59 F Right parotid 3.5 cm Parotidectomy NED, 7 mos
M male; F female; U gender unavailable; NED no evidence of disease; mos months.
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4 cm. Among the cases with follow-up available, no one
had recurrence or died because of the tumor. According
the clinically indolent behavior, most of the cases were
treated with parotidectomy without radiotherapy.
Grossly, the clinical suggestion of LGCCC is used to
be Warthin tumor according to the morphologic feature,
that is, a slowly growing cystic mass. Histologically, the
tumor is unencapsulated and composed of single or
multiple cysts with an intraductal proliferation. The cys-
tic cavity is in line with cytologically bland ductal cells.
The intraductal proliferation has a cribriform pattern
with “sieve-like spaces” similar to breast proliferations.
The majority of the tumor is intraductal; however, small
areas of invasion may be present. A total of 7/37 (19%)
cases summarized in Table 1 have focal stromal invasion.
The tumor cells usually display little cytologic atypia and
low mitotic rate [9]. Sometimes, the tumor cells have
PAS-positive/diastase-resistant microvacuoles and yellow-
brown, lipofuscin-like pigment. There is often associated
hemorrhage, cholesterol clefts and hemosiderin-laden
macrophages due to cyst rupture, while vascular and/or
perineural invasion and comedonecrosis is absent in
this tumor.
Immunohistochemically, LGCCC is characterized by
diffusely strong positive for S100. However, Weinreb
et al. [13] and Arai et al. [3] reported two cases of
LGCCC with rarely negative for S100. All tumors examined
for Her-2/neu oncoprotein, including our case, were
negative. Most of the tumor structures have continuous
myoepithelial rim confirmed by detection of myoepithelial
markers, such as, CK5/6, CK14, SMA, and p63, thus
clarifying an in situ nature of the neoplasm. Typically,
admixture of luminal and myoepithelial cells is absent.
The differential diagnosis of LGCCC includes PCV-
ACC, conventional SDC, cystadenocarcinoma, PLGA, car-
cinoma ex pleomorphic adenoma and MASC. PCV-ACC
resembles LGCCC according to the intracytoplasmic
PAS-positive/diastase-resistant granules (zymogen) and
hemosiderin [14]. In contrast to LGCCC, the more com-
mon microcystic growth pattern in PCV-ACC is usually
seen adjacent to cystopapillary areas and display granular
basophilic cytoplasm. PCV-ACC does not exhibit predom-
inance of the intraductal component in histology and the
intracytoplasmic vacuoles are uniform in size. Compared
with LGCCC, PCV-ACC is predominantly negative (about
90%) for S100 and focally expressed if present [9]. In
addition, PCV-ACC mainly occurs in young people, while
LGCCC usually affects older people.
Conventional SDC is a high-grade adenocarcinoma that
is common in elder people over 50 years of age [9].
Histologically, SDC resembles a high-grade invasive ductal
carcinoma of the breast, frequently accompanied by com-
edo necrosis and cribriform proliferation [9]. SDC exhibitsan apocrine-like appearance with positivity for GCDFP-15
and androgen receptor, which is occasionally observed in
LGCCC, but SDC is negative for S-100. In addition, SDC
usually exhibits a high Ki-67 labeling index. Occasional
cases of SDC in situ (SDCIS) have been described [15-17].
The in situ–like appearance or noninvasive cribriform
growth pattern make it hard to distinguish between SDCIS
and LGCCC. In contrast to LGCCC, the atypical cells in
SDCIS exhibit high nuclear pleomorphism and AR-
positive/S100-negative profile. Weinreb et al. [6] reported
a series of 3 intraductal neoplasms interpreted as LGCCC
with some nuclear atypia of the tumor cells, all expressing
AR and in 2 cases also showing S100 expression. Thus,
they consider their LGCCC cases to be a low-grade variant
of SDC with a potential for transformation into a high-
grade carcinoma. At present, the relationship between
LGCCC and SDCIS remains unclear although the current
WHO classification considering LGCCC as a variant of
cystadenocarcinoma. LGCCC may be either a separate en-
tity based on distinctive immunohistochemical profile or
an extremely low-grade end of the spectrum of SDCIS.
Recently, a new entity in the salivary gland called MASC
has been described [18,19], which shows a similar
microvacuolar appearance to LGCCC and may have any of
solid, cystic and papillary architectures. Similar to LGCCC,
MASC is also positive for S100. All these characteristics
make it difficult to distinguish between LGCCC and
MASC. Although no cases of MASC with an intraductal
growth pattern have been described, it should be noted that
only one IDC/LGCCC was included in the control group
tested for the ETV6-NTRK3 fusion in Skalova et al’s
original description of MASC. For now, the presence of a
complete myoepithelial layer around tumor nests is
considered specific to LGCCC instead of MASC.
In the current WHO classification, LGCCC is regard as a
variant of cystadenocarcinoma according to the histological
features. However, conventional cystadenocarcinoma tends
to be an invasive tumor and lacks the overall resemblance
to intraductal breast proliferation. PLGA and carcinoma
ex pleomorphic adenoma should also be considered
when rendering a diagnosis of LGCCC. PLGA can be
distinguished from LGCCC by its distinctive neurotropism
and infiltrative lobular, trabecular, and tubular patterns.
The transition from myoepithelium to stromal spindle cell
and myxoid or cartilaginous stroma is the typical features
of carcinoma ex pleomorphic adenoma, which is not
observed in LGCCC.
Both of the cases exhibited the typical features of
LGCCC, that is, intraductal proliferation and bland ductal
cells arranged in a cribriform pattern whichresembled the
low-grade breast lesions. Most of the tumor nests or crib-
riform structures in these two cases were rimming by the
continuous myoepithelialium which confirmed by p63,
thus, clarify an in situ nature of the neoplasm. The tumor
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In addition, the Ki67 index in our cases was under 5%. All
these findings supported the diagnosis of LGCCC, although
the dilated cystic structures were not observed in Case 2.
Conclusion
Our report illustrated two cases of LGCCC which was a
rare salivary tumor. LGCCC should be considered in the
differential diagnosis of salivary tumors to avoid rendering
a wrong diagnosis of other highly aggressive malignant
tumor of salivary gland.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in Chief of this Journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LW analyzed the data and wrote the manuscript as a major contributor. YL,
XL and DZ helped to perform the immunochemical staining. QL, XQ and EW
helped to revise the discussion section of this manuscript. All authors have
read and approved the final manuscript.
Received: 22 January 2013 Accepted: 13 February 2013
Published: 18 February 2013
References
1. Delgado R, Klimstra D, Albores-Saavedra J: Low grade salivary duct
carcinoma. A distinctive variant with a low grade histology and a
predominant intraductal growth pattern. Cancer 1996, 78:958–967.
2. Brandwein-Gensler M, Hille J, Wang BY, Urken M, Gordon R, Wang LJ,
Simpson JR, Simpson RH, Gnepp DR: Low-grade salivary duct carcinoma:
description of 16 cases. Am J Surg Pathol 2004, 28:1040–1044.
3. Arai A, Taki M, Mimaki S, Ueda M, Hori S: Low-grade cribriform
cystadenocarcinoma of the parotid gland: a case report. Auris Nasus
Larynx 2009, 36:725–728.
4. Laco J, Podhola M, Dolezalova H: Low-grade cribriform
cystadenocarcinoma of the parotid gland: a neoplasm with favorable
prognosis, distinct from salivary duct carcinoma. Int J Surg Pathol 2010,
18:369–373.
5. Nakazawa T, Kondo T, Yuminomochi T, Nakazawa K, Ishii Y, Mochizuki K,
Kawasaki T, Yamane T, Miyata M, Motosugi U, Katoh R: Fine-needle
aspiration biopsy of low-grade cribriform cystadenocarcinoma of the
salivary gland. Diagn Cytopathol 2011, 39:218–222.
6. Weinreb I: Intraductal carcinoma of salivary gland (so-called low-grade
cribriform cystadenocarcinoma) arising in an intraparotid lymph node.
Head Neck Pathol 2011, 5:321–325.
7. Tatemoto Y, Ohno A, Osaki T: Low malignant intraductal carcinoma on
the hard palate: a variant of salivary duct carcinoma? Eur J Cancer B Oral
Oncol 1996, 32B:275–277.
8. Nakatsuka S, Harada H, Fujiyama H, Takeda K, Kitamura K, Kimura H, Nagano
T, Ito M, Asada Y: An invasive adenocarcinoma of the accessory parotid
gland: a rare example developing from a low-grade cribriform
cystadenocarcinoma? Diagn Pathol 2011, 6:122.
9. Brandwein-Gensler M, Gnepp D, Skalova A, Nagano T: Tumours of the
salivary glands. In: Barnes L, Eveson JW, Reichart P, Sidransky D, eds. World
Health Organization Classifications of Tumours. Pathology and Genetics. Head
and Neck Tumours. Lyon, France: IARC Press; 2005:233–234.
10. Kondo T: A case of lipomatous pleomorphic adenoma in the parotid
gland: a case report. Diagn Pathol 2009, 4:16.11. Ponniah I, SureshKumar P, Karunakaran K, Shankar KA, Kumaran MG, Preeti
LN: Hemangioma in minor salivary glands: real or illusion. Diagn Pathol
2006, 1:21.
12. Schraven SP, Plontke SK, Syha R, Fend F, Wolburg H, Adam P: Dendritic cell
tumor in a salivary gland lymph node: a rare differential diagnosis of
salivary gland neoplasms. Diagn Pathol 2011, 6:94.
13. Weinreb I, Tabanda-Lichauco R, Van der Kwast T, Perez-Ordonez B: Low-
grade intraductal carcinoma of salivary gland: report of 3 cases with
marked apocrine differentiation. Am J Surg Pathol 2006, 30:1014–1021.
14. Ellis G, Simpson RHW: Acinic cell carcinoma. In World Health Organization
Classifications of Tumours. Pathology and Genetics. Head and Neck Tumours.
Edited by Barnes L, Eveson JW, Reichart P, Sidransky D. Lyon, France: IARC
Press; 2005:216–218.
15. Anderson C, Muller R, Piorkowski R, Knibbs DR, Vignoti P: Intraductal
carcinoma of major salivary gland. Cancer 1992, 69:609–614.
16. Cheuk W, Miliauskas JR, Chan JK: Intraductal carcinoma of the oral cavity:
a case report and a reappraisal of the concept of pure ductal carcinoma
in situ in salivary duct carcinoma. Am J Surg Pathol 2004, 28:266–270.
17. Simpson RH, Desai S, Di Palma S: Salivary duct carcinoma in situ of the
parotid gland. Histopathology 2008, 53:416–425.
18. Skalova A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, Starek I,
Geierova M, Simpson RH, Passador-Santos F, et al: Mammary analogue
secretory carcinoma of salivary glands, containing the ETV6-NTRK3
fusion gene: a hitherto undescribed salivary gland tumor entity. Am J
Surg Pathol 2010, 34:599–608.
19. Laco J, Svajdler M Jr, Andrejs J, Hrubala D, Hacova M, Vanecek T, Skalova A,
Ryska A: Mammary analog secretory carcinoma of salivary glands: A report of
2 cases with expression of basal/myoepithelial markers (calponin, CD10 and
p63 protein), Pathol Res Pract. 2013. http://10.1016/j.prp.2012.12.005.
doi:10.1186/1746-1596-8-28
Cite this article as: Wang et al.: Low-grade cribriform
cystadenocarcinoma of salivary glands: report of two cases and review
of the literature. Diagnostic Pathology 2013 8:28.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
